Answers are grounded in this paper and cite their sources.
Rozanolixizumab-noli (Rystiggo – UCB), a neonatal Fc receptor (FcRn) blocker, has been approved by the FDA for treatment of generalized myasthenia gravis in adults with anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies. It is the first drug to be approved for treatment of generalized myasthenia gravis in patients with anti-MuSK antibodies.
No takes yet. Share an insight, caveat, or question.
A 2024 study studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: